A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults

Exclusion Criteria

• •1. Known or persistent mental disorders that require medication intervention and may interfere with the subject's participation in the study.
• •2. Presence or suspicion of active viral, bacterial, fungal or parasitic infections;
• •3. History of recurrent or chronic infections;
• •4. History of epidemic meningococcal infection;
• •5. History of splenectomy or asplenia;
• •6. History of complement abnormalities or hereditary complement deficiencies;
• •7. Any skin conditions and/or tattoos that may interfere with the safety assessment of the injection site, or any relevant history of abdominal scar (surgery, burns, etc.);
• •8. Subjects who have tested positive for hepatitis B surface antigen, hepatitis C antibody, HIV antibody, and treponema pallidum antibody (optional );
• •9. Hepatic function abnormal.
• •10. Renal function abnormal.
• •11. Allergic condition (allergy to multiple drugs and food) or a known history of allergic reactions to oligonucleotides or hypersensitivity to subcutaneous injections;
• •12. Subjects who participate in other interventional clinical studies and receive interventional therapy within 30 days before the first dose of the study drug in this study or within the 5 half-lives of the study drug (including investigational drugs and investigational devices) in other interventional clinical studies, whichever is longer.
• •13. Subjects with history of drug abuse within 12 months.
• •14. Use of non-prescription drugs within 14 days prior to the first dose of the study drug or within the 5 half-lives of the non-prescription drugs (whichever is longer), unless the investigator determines that the medication is not clinically significant.
• •15. Subjects who have consumed more than 14 units of alcohol per week.
• •16. Heavy smoker.
• •17. Subjects who have donated or lost blood ≥ 480 mL within 3 months.
• •18. Subjects who have tested positive for pregnancy test; lactating women.